2024
FOS+ B cells: Key mediators of immunotherapy resistance in diverse cancer types
Zhang X, Ma J, Chen Y, Deng X, Zhang Y, Han Y, Tan J, Deng G, Ouyang Y, Zhou Y, Cai C, Zeng S, Shen H. FOS+ B cells: Key mediators of immunotherapy resistance in diverse cancer types. Molecular Therapy Oncology 2024, 32: 200895. PMID: 39583007, PMCID: PMC11584611, DOI: 10.1016/j.omton.2024.200895.Peer-Reviewed Original ResearchImmunotherapy resistanceB cellsPoor response to immunotherapyExpression of Blimp-1Cancer typesResponse to immunotherapyDifferentiation of B cellsB cell subpopulationsAssociated with poor response to immunotherapyPredicting treatment responseAffecting treatment efficacyDiverse cancer typesImmunotherapy efficacyImmunotherapy patientsTumor microenvironmentTreatment responsePlasma cellsImmunotherapyImmunosuppressive effectsBlimp-1Spatial transcriptomic analysisTreatment efficacyOvercome resistanceCancer treatmentImmunofluorescence analysisTWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer
Kumar V, Yochum Z, Devadassan P, Huang E, Miller E, Baruwal R, Rumde P, GaitherDavis A, Stabile L, Burns T. TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer. Oncogene 2024, 43: 1431-1444. PMID: 38485737, PMCID: PMC11068584, DOI: 10.1038/s41388-024-02987-5.Peer-Reviewed Original ResearchTyrosine kinase inhibitorsTKI resistanceMET amplificationEpithelial-mesenchymal transitionMET tyrosine kinase inhibitorsOvercome resistanceTyrosine kinase inhibitor resistanceTargetable oncogenic driversResistance in vitroEffective therapeutic strategySuppression of p27Inhibition of Twist1MET alterationsPDX modelsMET pathwayHGF/MET pathwayOncogenic driversLung cancerLung tumorigenesisKinase inhibitorsP27 expressionTherapeutic strategiesPharmacological inhibitionDownstream mediatorTwist1
2023
Abstract 3891: Epigenetic rewiring promotes antiandrogen resistance and metastasis via heterogenous oncogenic drivers in prostate cancer
li X, Deng S, Gonzalez J, Tirado C, Wang C, Johnson N, Metang L, Mu P. Abstract 3891: Epigenetic rewiring promotes antiandrogen resistance and metastasis via heterogenous oncogenic drivers in prostate cancer. Cancer Research 2023, 83: 3891-3891. DOI: 10.1158/1538-7445.am2023-3891.Peer-Reviewed Original ResearchResistant prostate cancerProstate cancerAntiandrogen resistanceAndrogen receptorResistant subclonesAmerican Association for Cancer Research annual meetingsOncogenic driversAggressive stage of prostate cancerCastration resistant prostate cancerStaging of prostate cancerGenomic copy number alterationsOvercome resistanceResistant tumor clonesMonths to 2 yearsTargeted therapy drugsResistance to antiandrogensAbstract Prostate cancerCopy number alterationsIncreased tumor heterogeneityDevelopment of novel biomarkersTherapy many patientsAntiandrogenic responseGeneration antiandrogensLoss of Chd1RB1 alterations
2018
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS
Kitajima S, Asahina H, Chen T, Guo S, Quiceno L, Cavanaugh J, Merlino A, Tange S, Terai H, Kim J, Wang X, Zhou S, Xu M, Wang S, Zhu Z, Thai T, Takahashi C, Wang Y, Neve R, Stinson S, Tamayo P, Watanabe H, Kirschmeier P, Wong K, Barbie D. Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS. Cancer Cell 2018, 34: 439-452.e6. PMID: 30205046, PMCID: PMC6422029, DOI: 10.1016/j.ccell.2018.08.009.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesAnimalsAntineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmHEK293 CellsHumansImmunity, InnateInsulin-Like Growth Factor ILung NeoplasmsMiceMice, TransgenicMitogen-Activated Protein Kinase KinasesPhosphoproteinsProtein Kinase InhibitorsProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)Transcription FactorsYAP-Signaling ProteinsConceptsGenetically engineered mouse modelsMediators of acquired resistanceDownstream of KRASBET inhibitor JQ1Effective therapeutic strategyTumor shrinkageTargeted therapyIntermittent treatmentYAP1 signalingMouse modelPathway inhibitionBET inhibitionTherapeutic strategiesInhibitor JQ1YAP1 upregulationOncogenic KrasBET inhibitorsOvercome resistancePromoter acetylationIntrinsic resistancePotential translationKRASMEKInnateInhibition
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply